Dasatinib-induced spleen contraction leads to transient lymphocytosis

The tyrosine kinase inhibitor dasatinib is approved for Philadelphia chromosome–positive leukemia, including chronic myeloid leukemia (CML). Although effective and well tolerated, patients typically exhibit a transient lymphocytosis after dasatinib uptake. To date, the underlying physiological proce...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcos-Jiménez, Ana, Carvoeiro, Daniela Claudino, Ruef, Nora, Cuesta-Mateos, Carlos, Roy-Vallejo, Emilia, Gómez-García de Soria, Valle, Laganá, Claudio, del Campo, Lourdes, Zubiaur, Pablo, Villapalos-García, Gonzalo, Abad-Santos, Francisco, Stein, Jens V., Muñoz-Calleja, Cecilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238846/
https://www.ncbi.nlm.nih.gov/pubmed/36583674
http://dx.doi.org/10.1182/bloodadvances.2022009279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238846/
https://www.ncbi.nlm.nih.gov/pubmed/36583674
http://dx.doi.org/10.1182/bloodadvances.2022009279

Ejemplares similares